Compare Morgan Stanley (MS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs GeneDx Holdings Corp — how do they compare? Morgan Stanley trades at $216.93 (market cap $338.22B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Morgan Stanley is far larger — about 131.1× GeneDx Holdings Corp's market cap, and Morgan Stanley pays a 2.14% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MS | WGS | |
|---|---|---|
Market Cap | $338.22B | $2.58B |
Sector | Financials | Technology |
52-Week High | $228.42 | $167.51 |
52-Week Low | $151.86 | $34.51 |
Dividend Yield | 2.14% | — |
Enterprise Value | — | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.33, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $239.58. Revenue grew to $66.0 billion in 2025, with net income margin expanding to 25.56%, and the company has beaten EPS estimates in recent quarters. Recent news highlights its role in leading Anthropic's IPO and advancements in AI integration for wealth management.
The outlook remains positive given strong earnings momentum and strategic initiatives, though risks include volatile cash flows from operations and high leverage. Wall Street sentiment is bullish with 55.77% of analysts rating it a Buy, supporting potential upside from current levels amid broader financial sector strength.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
